Sustained long-term dupilumab efficacy in adult patients with moderate-to-severe atopic dermatitis transitioning from weekly dosing to every other week: Results from an open-label extension trial

被引：0
|
作者：
Beck, Lisa A. [1 ]
Deleuran, Mette [2 ]
Hong, H. Chih-Ho [3 ,4 ]
Adam, David N. [4 ,5 ,6 ]
Hussain, Iftikhar [7 ]
Zhang, Haixin [8 ]
Shabbir, Arsalan [8 ]
Rodriguez Marco, Ainara [9 ]
Levit, Noah A. [8 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY USA
[2] Aarhus Univ Hosp, Aarhus, Denmark
[3] Univ British Columbia, Surrey, BC, Canada
[4] Canada Prob Med Res, Waterloo, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] CCA Med Res, Ajax, ON, Canada
[7] Vital Prospects Clin Res Inst PC, Tulsa, OK USA
[8] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[9] Sanofi Genzyme, Madrid, Spain
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
34385
引用
收藏
页码：AB206 / AB206
页数：1
相关论文
共 50 条
  • [31] Long-term efficacy of dupilumab in adults with moderate-tosevere atopic dermatitis (AD): Results from an open-label extension (OLE) trial up to 4 years
    Thyssen, Jacob P.
    Blauvelt, Andrew
    Lockshin, Benjamin
    Galus, Ryszard
    Lynde, Charles
    Xiao, Jing
    Levit, Noah A.
    Rodriguez Marco, Ainara
    Shabbir, Arsalan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB180 - AB180
  • [32] JAAD Game Changers: Dupilumab shows long-term safety and efficacy in patients with moderate-to-severe atopic dermatitis enrolled in a phase 3 open-label extension study
    Wohltmann, Wendi E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (03) : 613 - 613
  • [33] Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    de Bruin-Weller, Marjolein
    Chen, Zhen
    Khokhar, Faisal A.
    Zhang, Meng
    Ozturk, Zafer E.
    Shumel, Brad
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1608 - 1616
  • [34] Laboratory safety of long-term dupilumab treatment in a 5-year open-label extension study of adults with moderate-to-severe atopic dermatitis
    Beck, L. A.
    Bissonnette, R.
    Deleuran, M.
    Nakahara, T.
    Galus, R.
    Khokhar, F. A.
    Coleman, A.
    Gherardi, G.
    Chen, Z.
    Avetisova, E.
    Dubost-Brama, A.
    Shabbir, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S364 - S364
  • [35] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, A.
    Guttman-Yassky, E.
    Hussain, I.
    Chen, Z.
    Mina-Osorio, P.
    Rossi, A. B.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (04) : E96 - E96
  • [36] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: Results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, Andrew
    Guttman, Emma
    Hussain, Iftikhar
    Chen, Zhen
    Mina-Osorio, Paola
    Rossi, Ana Beatris
    Bansal, Ashish
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB141 - AB141
  • [37] Long-term efficacy and safety of dupilumab in adolescents with atopic dermatitis: results from an open-label extension trial (LIBERTY AD PED-OLE)
    Blauvelt, A.
    Guttman-Yassky, E.
    Hussain, I.
    Worrell, R.
    Chen, Z.
    Mina-Osorio, P.
    Rossi, A. B.
    Bansal, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2021, 62 : 29 - 31
  • [38] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Papp, Kim A.
    de Vente, Saskia
    Zeng, Jiewei
    Flack, Mary
    Padilla, Byron
    Tyring, Stephen K.
    DERMATOLOGY AND THERAPY, 2021, 11 (02) : 487 - 497
  • [39] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
    Kim A. Papp
    Saskia de Vente
    Jiewei Zeng
    Mary Flack
    Byron Padilla
    Stephen K. Tyring
    Dermatology and Therapy, 2021, 11 : 487 - 497
  • [40] Long-term efficacy and safety of stapokibart for moderate-to-severe atopic dermatitis: 52-week results from a phase 3 trial
    Zhao, Yan
    Zhang, Litao
    Wu, Liming
    Yang, Bin
    Wang, Jinyan
    Li, Yumei
    Li, Jingyi
    Diao, Qingchun
    Sun, Qing
    Zhu, Xiaohong
    Man, Xiaoyong
    Wang, Lihua
    Li, Linfeng
    Feng, Yanyan
    Zeng, Huiming
    Cai, Tao
    Ren, Hong
    Lu, Jianyun
    Lu, Qianjin
    Tao, Xiaohua
    Xiao, Rong
    Ji, Chao
    Li, Fuqiu
    Zhang, Jianzhong
    ALLERGY, 2024,
12345